Vaxxinity, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by UNITED BIOMEDICAL INC, was filed 21 Jun 2022.
Vaxxinity, Inc.: what insiders have been doing
Vaxxinity, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Vaxxinity, Inc. in twelve months, the latest record being from 8 September 2023.
Our records for Vaxxinity, Inc. go back to 2021, with 15 purchases and 34 sales on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- +17.0%Entry US$1.94 · Close at T+365 US$2.27
- -12.7%Entry US$2.28 · Close at T+365 US$1.99
- -12.7%Entry US$2.28 · Close at T+365 US$1.99
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
- 4,786 shares@ US$1.78720.0% of flowClass A Common StockSEC:0001062993-23-017880:5
- 507 shares@ US$1.8823Class A Common StockSEC:0001062993-23-017880:2
- 892 shares@ US$1.8823Class A Common StockSEC:0001062993-23-017880:3
- 2,189 shares@ US$1.8823Class A Common StockSEC:0001062993-23-017880:4
- 5,308 shares@ US$1.88230.0% of flowClass A Common StockSEC:0001062993-23-017880:1
- 1,939 shares@ US$1.7872Class A Common StockSEC:0001062993-23-017880:7
- 3,413 shares@ US$1.7872Class A common stockSEC:0001062993-23-017880:8
- 5,911 shares@ US$1.670.0% of flowClass A common stockSEC:0001062993-23-017880:10
- 2,395 shares@ US$1.67Class A Common StockSEC:0001062993-23-017880:12
- 1,251 shares@ US$1.88234.1% of flowClass A Common StockSEC:0001062993-23-017880:0
- 46,500 shares@ US$1.210.0% of flowClass A common stockSEC:0001437749-23-012008:1
- 429,037 shares@ €0.5163.0% of flowClass A common stockSEC:0001437749-23-012008:0
- 405,217 shares@ US$3.3514Class A common stockSEC:0001062993-23-001392:1
- 95,475 shares@ US$3.351455.5% of flowClass A common stockSEC:0001062993-23-001392:0
- 11,121 shares@ US$2.56820.0% of flowClass A Common StockSEC:0001062993-22-023345:3
- 270,964 shares@ US$2.9717Class A Common StockSEC:0001062993-22-023345:1
- 2,620 shares@ US$2.5682Class A Common StockSEC:0001062993-22-023345:2
- 63,843 shares@ US$2.971734.3% of flowClass A Common StockSEC:0001062993-22-023345:0
- 2,234 shares@ US$2.4029Class A Common StockSEC:0001062993-22-019372:1
- 3,934 shares@ US$2.4029Class A Common StockSEC:0001062993-22-019372:2
- 25,243 shares@ US$2.40290.0% of flowClass A Common StockSEC:0001062993-22-019372:3
- 5,947 shares@ US$2.402926.8% of flowClass A Common StockSEC:0001062993-22-019372:0
- 20,000 shares@ US$0.000.0% of flowClass A common stockSEC:0001437749-22-021457:1
- 26,005 shares@ US$0.000.0% of flowClass A common stockSEC:0001437749-22-021457:2
- 2,640 shares@ US$0.00020.0% of flowClass A common stockSEC:0001437749-22-021457:3
25 of 91 declarations
About Vaxxinity, Inc.
Vaxxinity, Inc. is a United States-based biotechnology company listed on the NASDAQ under the ticker VAXX. The company is headquartered in Dallas, Texas, United States, with its public business address shown at 2622 Commerce St., Dallas, TX 75226. Vaxxinity describes itself as a developer of next-generation immunotherapeutic vaccines and antibody-inducing medicines aimed at chronic diseases rather than only traditional infectious-disease vaccination. ([vaxxinity.com](https://vaxxinity.com/?utm_source=openai))
Historically, Vaxxinity emerged from the United Biomedical ecosystem and was built around the idea of commercializing a synthetic-peptide vaccine approach at scale. Management positions the company as a platform biotech designed to create medicines that harness the immune system to generate antibodies, with an emphasis on affordability, stability, and manufacturability. The company’s official science materials state that its AIM (Active Immunotherapy Medicine) platform uses synthetic peptides to selectively activate the immune system and that the platform has been validated through animal-health use and multiple human clinical trials. ([vaxxinity.com](https://vaxxinity.com/our-science/?utm_source=openai))
Read moreShow less
From an operating perspective, Vaxxinity is primarily a clinical-stage company. It does not rely on a broad commercial portfolio of marketed products; instead, value creation is tied to a pipeline of investigational assets. Its main programs include UB-311 for Alzheimer’s disease, UB-312 targeting aggregated alpha-synuclein for Parkinson’s disease and related synucleinopathies, VXX-401 for lowering LDL cholesterol via PCSK9 biology, and a COVID-related program built around a multitope immune response. This gives Vaxxinity exposure to several large therapeutic markets, but also makes the investment case highly dependent on clinical outcomes and regulatory progress. ([vaxxinity.com](https://vaxxinity.com/our-pipeline/?utm_source=openai))
In competitive terms, Vaxxinity differentiates itself through a synthetic peptide platform and a value proposition centered on cold-chain practicality and scalable manufacturing. The company emphasizes that some of its candidates can be stored and shipped at conventional 2–8°C temperatures, which could be advantageous if later-stage development succeeds and commercialization becomes possible. That said, it competes in highly crowded and scientifically demanding fields, including neurology, cardiovascular disease, and infectious disease, where large-cap pharma and well-funded biotech peers have materially greater resources. ([vaxxinity.com](https://vaxxinity.com/our-science/?utm_source=openai))
Geographically, Vaxxinity is a U.S. company with an international development footprint, but its corporate identity, listing venue, and headquarters are clearly American. For investors in France, Belgium, and Switzerland, VAXX should be viewed as a NASDAQ-listed biotech with asymmetric upside potential but substantial execution risk. Recent company messaging continues to highlight pipeline advancement, especially in Alzheimer’s and Parkinson’s-related programs, underscoring that the near-term equity story is still driven by research progress rather than product revenue. ([vaxxinity.com](https://vaxxinity.com/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
